Abstract:5059 Background: Response to androgen signaling inhibitors is highly variable and dictates prognosis in castration resistant prostate cancer (CRPC). The development of effective combinations for CRPC has been hampered by the absence of biomarkers to identify its distinct biological subsets, obligating the homogeneous application of therapies to a heterogeneous disease in clinical trials. We previously defined the aggressive variant prostate cancers as a framework for the study of those with poor responses to androgen signaling inhibitors (dubbed ‘androgen indifferent’) and observed improved outcomes in this subset when carboplatin was added to cabazitaxel (CABCARB). In contrast, results of prospective trials suggested that anti-CTLA-4 therapy may benefit patients with androgen responsive disease. We hypothesized that said combinations applied to subsets defined by early marker declines to androgen ablation would improve overall survival (OS) over historical data in unselected CRPC. Methods: In an open-label, phase II trial (NCT02703623), men with mCRPC received abiraterone and apalutamide (ABIpAPA; Mod 1). At week 8, patients had either a ‘satisfactory’ (S) decline in PSA (≥ 50% from baseline) and CTC (≤5/7.5mL) or ‘unsatisfactory’ (US). S patients ( Mod 2) were randomized to continue ABIpAPA alone ( 2A) or with up to 4 cycles of ipilimumab (IPI, 2B). US patients ( Mod 3) continued ABIpAPA with up to 10 cycles of CABCARB. Thereafter patients continued ABIpAPA until progression. OS was calculated from entry into Mod 2 or 3. Based on historical data, the estimated median OS for men in Mod 2 and Mod 3 were 36 and 16 months respectively. Results: 195 men with CRPC were enrolled between May 2016 and August 2019. 128 (67%) were allocated to S of which 64 each were randomized to receive IPI vs. not. 3 went off study during Mod 1 without clinical decline. Of 64 patients allocated to US, 59 were treated with CABCARB on study . Men in US were more likely to have had de novo metastasis (33% vs 59%, p < 0.001), RECIST measurable disease (23% vs 42%, p = 0.01), and liver metastases (3% vs 13%, p = 0.01). Differences in baseline circulating markers between the groups are shown in Table 1. Serious adverse events were reported for 3 (4.7%), 21 (33%), and 6 (10.2%) patients for M od 2A, 2B, and 3 respectively. One death due to neutropenic sepsis occurred in Mod 3. At a median follow-up of 48 months, the median (95% CI) OS in Mod2A was 44.3 (38.1, 47.7) months, 41.4 (33.3 months, not reached) in Mod 2B, and 18.7 (14.3, 36.3) months in Mod 3. Conclusions: These data substantiate the impact of underlying biology on CRPC patient outcomes and the urgent need for biomarkers that can enable the development of therapies specific to each subset. Correlative studies to identify said biomarkers will be presented. Clinical trial information: NCT02703623.

Evaluating PSA nadir drift in high-risk and metastatic prostate cancer.

Management of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy

Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies

Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.

Real-world treatment patterns for patients with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer.

Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.

How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy

What criteria do clinicians use to classify men as “high risk” among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer?

Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High‐Risk Prostate Cancer

[Predictive Factor Analysis of Time to Progression of Castration-Resistant Prostate Cancer after Androgen Deprivation Therapy].

The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy

Evaluation of Psa Patterns in Patients with Localized Prostate Cancer Treated with Radiation Therapy and Androgen Deprivation Therapy

Clinico-Pathological Factors and AR-LBD Mutations in Early and Late Castration-Resistant Prostate Cancer

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria

Baseline PSMA-PET/CT As a Predictor of PSA Persistence Following Radical Prostatectomy in High-Risk Nonmetastatic Prostate Cancer Patients Receiving Neoadjuvant Therapy.

Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable‐risk prostate cancer: A secondary analysis of a randomized clinical trial

Prostate‐specific antigen nadir and testosterone level at prostate‐specific antigen failure following radiation and androgen suppression therapy for unfavorable‐risk prostate cancer and the risk of all‐cause and prostate cancer–specific mortality

DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC.

Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents